Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IMNM declined for three days, in 261 of 303 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
IMNM moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IMNM crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for IMNM entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 238 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IMNM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.690) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KROS saw its Momentum Indicator move below the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 75 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 82%.
The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 32 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
KROS moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
KROS broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +6.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 229 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 191 of 230 cases where KROS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.853) is normal, around the industry mean (26.782). P/E Ratio (4.778) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IMNM | KROS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 95 | |
PRICE GROWTH RATING 1..100 | 65 | 57 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 44 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KROS's Valuation (51) in the null industry is in the same range as IMNM (65). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.
KROS's Profit vs Risk Rating (100) in the null industry is in the same range as IMNM (100). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.
KROS's SMR Rating (95) in the null industry is in the same range as IMNM (98). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.
KROS's Price Growth Rating (57) in the null industry is in the same range as IMNM (65). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.
KROS's P/E Growth Rating (100) in the null industry is in the same range as IMNM (100). This means that KROS’s stock grew similarly to IMNM’s over the last 12 months.
| IMNM | KROS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 83% |
| Momentum ODDS (%) | N/A | 2 days ago 82% |
| MACD ODDS (%) | N/A | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 76% |
| Advances ODDS (%) | 8 days ago 83% | 8 days ago 77% |
| Declines ODDS (%) | 3 days ago 86% | 3 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 83% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMNM’s FA Score shows that 0 FA rating(s) are green while KROS’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMNM’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 3 bullish TA indicator(s).
IMNM (@Biotechnology) experienced а -9.89% price change this week, while KROS (@Biotechnology) price change was -4.64% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.70%. For the same industry, the average monthly price growth was -18.24%, and the average quarterly price growth was -21.46%.
IMNM is expected to report earnings on Nov 16, 2026.
KROS is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SLVX | 12.71 | 0.57 | +4.70% |
| Nicholas Silver Income ETF (SLVX) | |||
| GMOD | 27.64 | 0.18 | +0.65% |
| GMO Dynamic Allocation ETF (GMOD) | |||
| CMF | 54.79 | 0.34 | +0.62% |
| iShares California Muni Bond ETF (CMF) | |||
| DABS | 49.71 | 0.10 | +0.20% |
| Doubleline Asset-Backed Securities ETF | |||
| CHW | 7.94 | N/A | N/A |
| Calamos Global Dynamic Income Fund | |||
A.I.dvisor indicates that over the last year, KROS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To KROS | 1D Price Change % | ||
|---|---|---|---|---|
| KROS | 100% | +0.45% | ||
| AXON - KROS | 43% Loosely correlated | +2.15% | ||
| ABEO - KROS | 43% Loosely correlated | +6.65% | ||
| EYPT - KROS | 43% Loosely correlated | +4.32% | ||
| IMNM - KROS | 42% Loosely correlated | +1.16% | ||
| SANA - KROS | 42% Loosely correlated | +6.22% | ||
More | ||||